The Spanish diagnostics group Werfen, based in Barcelona, is acquiring the Hungarian company Omixon for around USD 25 million.
Omixon Biocomputing Kft. was founded in 2011. It advanced from a software developer for genetics to a specialist for sequencing technologies (NGS) used in transplant diagnostics.
Venture capitalists such as Fastventures Zrt. and Lochlomond Holding as well as Euroventures were involved in financing the company.
Werfen, with technology centers in the USA and Europe, has an annual turnover of over USD 2 billion and employs more than 5,000 people.